Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 2, 2023, we reported on a study published in JAMA Network Open that examined the prospective association between ultraprocessed foods (UPFs) and its components with incident depression.
The study
Investigators conducted a prospective cohort study of 31 712 women (mean age, 52 years; 95.2% non-Hispanic White) aged 42 to 62 years who were enrolled in the Nurses’ Health Study II between 2003 and 2017 and free of depression of baseline. Every 4 years, the participants’ diet was evaluated using validated food frequency questionnaires.
Regarding depression, investigators used 2 definitions: “(1) a strict definition requiring self-reported clinician-diagnosed depression and regular antidepressant use and (2) a broad definition requiring clinical diagnosis and/or antidepressant use.”
Findings
Compared with those in the lowest quintile of UPF intake, participants in the highest quintile had an increased risk of depression—using both the strict definition and the broad definition.
When researchers examined the association of specific UPF components with risk of depression, they found that only artificial sweetened beverages and artificial sweeteners were associated with greater risk of depression.
Authors' comment
"These findings suggest that greater UPF intake, particularly artificial sweeteners and artificially sweetened beverages, is associated with increased risk of depression. Although the mechanism associating UPF to depression is unknown, recent experimental data suggests that artificial sweeteners elicit purinergic transmission in the brain, which may be involved in the etiopathogenesis of depression."
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.